Research Article
Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes
Table 2
Changes in clinical parameters from baseline with dapagliflozin or empagliflozin.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Data are shown as median (IQR). ALT: alanine aminotransferase; CHOT(T): total cholesterol; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FPG: fasting plasma glucose; HbA1c: hemoglobin A1c; HDL-C: high-density lipoprotein-cholesterol level; LDL-C: low density lipoprotein-cholesterol level; SBP: systolic blood pressure; Scr: serum creatinine. †Wilcoxon sign rank test was used to compare of differences within groups measured at baseline and 36 months. ‡Mann–Whitney test was used to compare of differences between groups measured at baseline and 36 months. value <0.05 were considered statistically significant. |